Delving into the Latest Updates on Sironax USA, Inc. with Synapse

概览

关联

1

项与 Sironax USA, Inc. 相关的药物

SIR1-365

靶点

RIPK1

作用机制

RIPK1抑制剂

在研机构

SIRONAX AUS PTY LTD [+1]

原研机构

维泰瑞隆（北京）生物科技有限公司初创企业

在研适应症

新型冠状病毒感染 [+1]

非在研适应症

炎症 [+2]

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

1

项与 Sironax USA, Inc. 相关的临床试验

NCT04622332

/ Completed临床1期

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

Primary Objective:
• To evaluate overall safety and tolerability of SIR1-365 in patients with severe COVID-19
Secondary Objectives:
To assess the clinical efficacy of SIR1-365 in patients with severe COVID-19
To assess the effects of SIR1-365 on multiple inflammatory biomarker levels including C-reactive protein (CRP), ferritin, lymphocyte and neutrophil counts, cytokines, and chemokines
To assess the effects of SIR1-365 on biomarkers indicative of target engagement in patients with severe COVID-19
To assess the effects of SIR1-365 on biomarkers indicative of kidney injury in patients with severe COVID-19
To assess the effects of SIR1-365 on biomarkers indicative of cardiovascular endothelial cell damage in patients with severe COVID-19
To characterize plasma pharmacokinetics (PK) of SIR1-365 in patients with severe COVID-19

开始日期2020-12-18

申办/合作机构

Sironax USA, Inc.

100 项与 Sironax USA, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Sironax USA, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Sironax USA, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Sironax USA, Inc. 相关的转化医学

登录后查看更多信息